

**SUPPLEMENTAL TABLE 1: Univariate analysis and multivariable analysis of overall survival and radiographic progression free survival in the entire cohort**

	Univariate analysis				Multivariable analysis*			
	Overall survival		Radiographic progression free survival		Overall survival		Radiographic progression free survival	
	HR (95% CI)	p value	HR (95% CI)	p value	HR (95% CI)	p value	HR (95% CI)	p value
<b>Age: &gt; 70 yrs</b>	1.02 (0.65-1.59)	0.931	0.77 (0.55-1.09)	0.143	NA	NA	1.07 (0.74-1.55)	0.724
<b>Karnofsky Performance Status: ≤ 80</b>	2.79 (1.70-4.58)	<0.001	1.18 (0.84-1.67)	0.343	1.83 (1.07-3.14)	0.028	NA	NA
<b>Baseline PSA: &gt; 60 ng/mL</b>	3.15 (1.97-5.04)	<0.001	1.92 (1.35-2.74)	<0.001	1.27 (0.73-2.21)	0.399	1.09 (0.71-1.68)	0.697
<b>Time from diagnosis to first <sup>177</sup>Lu-PRLT treatment: &gt; 5 years</b>	0.56 (0.36-0.87)	0.010	0.57 (0.40-0.80)	0.001	0.61 (0.38-0.97)	0.037	0.54 (0.37-0.78)	0.001
<b>Cumulative administered activity: &gt; 16 GBq</b>	0.36 (0.23-0.57)	<0.001	0.82 (0.58-1.16)	0.265	0.50 (0.31-0.81)	0.005	NA	NA
<b>Bone metastases: yes</b>	5.90 (2.15-16.19)	0.001	1.84 (1.10-3.07)	0.019	2.32 (0.81-6.69)	0.119	1.07 (0.61-1.87)	0.815
<b>Visceral metastases: yes</b>	2.24 (1.40-3.59)	0.001	1.90 (1.28-2.84)	0.002	1.69 (1.02-2.80)	0.042	1.46 (0.96-2.23)	0.080
<b>Baseline haemoglobin: ≤ 7.5 mmol/L</b>	4.27 (2.60-6.99)	<0.001	2.21 (1.55-3.15)	<0.001	2.06 (1.18-3.58)	0.011	1.55 (1.01-2.37)	0.043
<b>Baseline ALP*: ≥ 220 U/L</b>	3.96 (2.44-6.44)	<0.001	3.04 (2.04-4.52)	<0.001	1.83 (1.08-3.10)	0.024	2.13 (1.35-3.37)	0.001
<b>Taxane Chemotherapy: yes</b>	2.55 (1.60-4.06)	<0.001	1.71 (1.20-2.43)	0.003	1.53 (0.88-2.67)	0.134	1.26 (0.84-1.89)	0.263

\*Data available for 166 patients